RANBAXYS JV IN JAPAN UNVEILS MAIDEN DRUG

Nihon Pharmaceutical Industry (NPI), the Japanese joint venture company of Ranbaxy Laboratories, has launched its first collaborative research product --Vogseal in Japan. NPI is a venture between Ranbaxy and Nippon Chemiphar. Vogseal, an anti-diabetic drug brand of the molecule Voglibose, is the first product developed by the joint venture. The product will be sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry label and will be marketed and promoted to doctors in hospitals as well as in clinics by field forces of Nippon Chemiphar and Nihon Pharmaceutical Industry.

Business Standard (http://www.business-standard.com/common/storypage.php?storyflag=y&leftnm=lmnu1&leftindx=1&lselect=1&chklogin=N&autono=195765)